Share ownership BGI Genomics Co., Ltd.

300676

CNE100003449

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2025-01-20			5-day change	1st Jan Change
39.16 ^CNY	-0.03%		+0.46%	-6.70%

Oct. 25	BGI Genomics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
Sep. 13	BGI Genomics Gets Registration for Expanded Use of Hereditary Deafness Gene Detection Kit	MT

Share class: BGI Genomics Co., Ltd.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	415,821,575	217,706,626 ( 52.36 %)	0	52.36 %

Major shareholders: BGI Genomics Co., Ltd.

Name	Equities	%	Valuation
Jian Wang 37.32 %	153,344,167	37.32 %	882 M ¥
Jun Wang 8.389 %	34,470,455	8.389 %	198 M ¥
Wanjia Asset Management Co., Ltd. 3.139 %	12,899,558	3.139 %	74 M ¥
Hwabao WP Fund Management Co., Ltd. 1.949 %	8,009,573	1.949 %	46 M ¥
Nanji E Commerce Co. Ltd. ESOP 2 0.9734 %	4,000,141	0.9734 %	23 M ¥
China Southern Asset Management Co., Ltd. 0.8439 %	3,467,820	0.8439 %	20 M ¥
E Fund Management Co., Ltd. 0.7875 %	3,235,966	0.7875 %	19 M ¥
Qian Xing He 0.6865 %	2,820,936	0.6865 %	16 M ¥
Guotai Asset Management Co., Ltd. 0.5163 %	2,121,567	0.5163 %	12 M ¥
GF Fund Management Co., Ltd. 0.4472 %	1,837,636	0.4472 %	11 M ¥
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Jian Wang 63.66 %	1,903,350	63.66 %	11 M ¥

Breakdown by shareholder type

Individuals	46.39%
Institutional	8.69%
Other	0.97%
Unknown	43.95%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	46.39%
China	9.64%
Hong Kong	0.01%

Based on 1000 largest holdings

BGI Genomics Co., Ltd. is a leading provider of genomic and proteomic sequencing services primarily to academic institutions, pharmaceutical companies and healthcare providers. The company also provides genomic solutions for biomarker research and development, screening for some of the trisomies present at birth (trisomy 21, trisomy 18 and trisomy 13) and solutions for neo-antigen identification for immuno-oncology research.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-04-23 - Q4 2024 Earnings Release (Projected)

More about the company